Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | RP-6306 |
Trade Name | |
Synonyms | RP6306|RP 6306|Lunresertib |
Drug Descriptions |
RP-6306 is a PKMYT1 inhibitor, which may decrease CDK1 phosphorylation, leading to cell cycle arrest, apoptosis, and decreased tumor growth (Cancer Res (2025) 85 (8_Supplement_2): CT262, NCI Drug Dictionary). |
DrugClasses | |
CAS Registry Number | 2719793-90-3 |
NCIT ID | C179323 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Carboplatin + Paclitaxel + RP-6306 | Carboplatin Paclitaxel RP-6306 | 0 | 1 |
Debio 0123 + RP-6306 | Debio 0123 RP-6306 | 0 | 1 |
Fluorouracil + Irinotecan + Leucovorin + RP-6306 | Fluorouracil Irinotecan Leucovorin RP-6306 | 0 | 2 |
Gemcitabine + RP-6306 | Gemcitabine RP-6306 | 0 | 3 |
RP-3500 + RP-6306 | RP-3500 RP-6306 | 1 | 2 |
RP-6306 | RP-6306 | 2 | 1 |
RP-6306 + Trastuzumab | RP-6306 Trastuzumab | 0 | 1 |